The other thing Karst Peak assumes is a 10x cash flow multiple for Trof "giving consideration to patent life and paediatric orphan drug exclusivity". Out of curiosity, is there a reason you are using 25x crem? Or more broadly is there a reason NEU might get the advantage longer than c.10 years?
The other thing Karst Peak assumes is a 10x cash flow multiple...
-
- There are more pages in this discussion • 1,540 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.21 |
Change
-0.130(0.85%) |
Mkt cap ! $1.944B | |||
| Open | High | Low | Value | Volume |
| $15.19 | $15.47 | $15.07 | $6.450M | 422.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1938 | $15.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.29 | 54 | 1 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |